SCHEMBL6133413

SCHEMBL6133413

CCOC(=O)c1nc(-c2cccc(Cl)c2)c(-c2ccc(=O)n(C(C)C)n2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.41
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
POLB P06746 1/20 0.39
DYRK3 O43781 1/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK2 Q92630 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
PTGS2 P35354 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
TP53 P04637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133357 0.89 TRPM8 (0.45) PDE4APDE4BPDE4CPDE4DTRPM8
SCHEMBL6133924 0.89 PTGS2 (0.44) PDE4APDE4BPDE4CPDE4DTRPM8
SCHEMBL6134087 0.86 POLB (0.40) POLBALDH1A1KDM4E
SCHEMBL6134607 0.86 POLB (0.39) PDE4BJAK2POLBALDH1A1KDM4E
SCHEMBL6133158 0.83 PTGS2 (0.56) TRPM8L3MBTL1GABRA2GABRB2PTGS2
SCHEMBL6133317 0.81 MAPT (0.46) PDE4APDE4BPDE4CPDE4DPOLB
SCHEMBL6133353 0.80 ALDH1A1 (0.47) L3MBTL1JAK2JAK3POLBPTGS2
SCHEMBL6134397 0.80 TGFBR1 (0.53) POLBALDH1A1KDM4EMAPTLMNA
SCHEMBL6134702 0.80 ADORA2A (0.49) L3MBTL1POLBALDH1A1KDM4EMAPT
SCHEMBL6134322 0.76 PTGS2 (0.46) PDE4APDE4BPDE4CPDE4DTRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR PDE4A 2634/4885PDE4B 2146/4885PDE4C 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.